Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Fixed-Dose Combinations

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets

Last Updated: December 14, 2018; Last Reviewed: December 14, 2018

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tabletsa
Brand Name by Class NRTIs NNRTIs INSTIs PIs PK Enhancers
ABC 3TC ZDV FTC TDF TAFb EFV RPV BICb DTG EVGb ATV DRV LPVc COBI RTV
NRTI
Cimduo   X     X                      
Combivir, Generic   X X                          
Descovy       X    X                    
Epzicom, Generic  X  X                            
Temixys    X                          
Trizivir, Generic  X  X  X                          
Truvada        X  X                      
NRTI/NNRTI
Atripla        X  X    X                  
Complera        X  X      X                
Odefsey        X    X    X                
Symfi or Symfi Lo    X      X    X                  
NRTI/INSTI
Biktarvy        X    X      X              
Triumeq  X  X                X            
NNRTI/INSTI
Juluca                X    X            
NRTI/INSTI/COBI
Genvoya        X    X          X        X  
Stribild        X  X            X        X  
NRTI/PI/COBI
Symtuza        X    X              X    X  
PI/COBI
Evotaz                        X      X  
Prezcobix                          X    X  
PI/RTV
Kaletra                            X    X
a This table may include recently approved FDCs that have not yet been added to individual drug sections in the Pediatric Antiretroviral Drug Information Appendix (see individual drug components for details), and it does not include FDCs for individual component drugs that were recently approved and have not been added to the Pediatric Antiretroviral Drug Appendix (e.g., Doravirine and the FDC Delstrigo).
b TAF, BIC, and EVG are only available in FDC tablets. However, TAF 25 mg tablets (Vemlidy) are FDA-approved for treatment of HBV. In select circumstances, TAF might be used as one component of a combination ARV regimen, with dosing recommendations similar to those for Descovy.
c LPV is only available in fixed-dose tablets or solution.

Key to Acronyms: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV = atazanavir; BIC = bictegravir; COBI = cobicistat; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FDA = Food and Drug Administration; FDC = fixed-dose combination; FTC = emtricitabine; HBV = hepatitis B virus; LPV = lopinavir; LPV/r = lopinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside and nucleotide reverse transcriptase inhibitor; PI = protease inhibitor; PK = pharmacokinetic; RPV = rilpivirine; RTV = ritonavir; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

Download Guidelines